Lataa...
BAP31, a promising target for the immunotherapy of malignant melanomas
PURPOSE: Malignant melanoma’s (MM) incidence is rising faster than that of any other cancer in the US and the overall survival at 5 years is less than 10%. B cell associated protein 31 (BAP31) is overexpressed in most MMs and might be a promising target for immunotherapy of this disease. EXPERIMENTA...
Tallennettuna:
| Julkaisussa: | J Exp Clin Cancer Res |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4405826/ https://ncbi.nlm.nih.gov/pubmed/25903101 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-015-0153-6 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|